51 results about "Dextran sodium sulfate" patented technology

The invention discloses application of copper-amino acid nano enzyme in preparation of anti-inflammatory drugs, and relates to the technical field of biomedical new materials, amino acids comprise glycine, arginine, histidine, threonine, phenylalanine and cysteine; the ratio of the amino acid to the copper ions is 1: (0.5-5), and the synthesis temperature of the copper-cysteine nano enzyme is 25-125 DEG C. The copper-amino acid nano-enzyme library established by the invention has efficient hydroxyl free radical, superoxide free radical and hydrogen peroxide scavenging activity; wherein the copper-cysteine nano-enzyme shows the highest enzymatic activity, and shows low toxicity and good biocompatibility in both the cell level and the animal level; meanwhile, the copper-cysteine nano-enzyme also shows anti-inflammatory activity and anti-oxidative stress activity, can remarkably improve cell inflammation and body inflammation, relieves and treats dextran sodium sulfate induced mouse ulcerative colitis, and can be further applied to preparation of drugs for treating inflammatory bowel diseases.

The invention discloses a crocodile polypeptide with anti-inflammatory and intestinal flora regulating functions and a preparation method thereof, belongs to the technical field of functional polypeptide preparation, and particularly relates to a preparation method of the crocodile polypeptide, an anti-inflammatory effect of the crocodile polypeptide and a regulating effect of the crocodile polypeptide on intestinal flora in ulcerative colitis inflammation. According to the preparation method, the crocodile polypeptide is prepared by combining multiple physical processing with enzymolysis, so that the purity and the biological activity of the crocodile polypeptide are improved. On the basis, a lipopolysaccharide-induced THP-1 in-vitro cell inflammation model and a dextran sodium sulfate-induced mouse in-vivo ulcerative colitis inflammation model are established, and the in-vivo and in-vitro anti-inflammatory effect of the crocodile polypeptide is further researched. The crocodile polypeptide prepared by the invention has a remarkable inhibition effect on THP-1 cell inflammation induced by lipopolysaccharide. Meanwhile, the crocodile polypeptide prepared by the preparation method disclosed by the invention has an adjusting effect on intestinal flora. The food or functional food with the effects of relieving ulcerative colitis and regulating intestinal flora can be prepared.

The invention discloses a construction method and application of a probiotic engineering bacterium EcNpAm targeting animal intestinal tracts and improving inflammation. According to the present invention, the heterologous expression of the immunomodulatory protein Amuc1100 is successfully achieved through the gene engineering technology by using the Escherichia coli Niss1917 (EcN) as the host and using the anaerobic inducible plasmid pnirBMisL as the expression vector, and the novel engineering bacterium EcNpAm suitable for the animal intestinal anaerobic environment is constructed; furthermore, the expression efficiency of the target protein is represented by fusion expression of green fluorescent protein (GFP). The engineering bacterium is applied to prevention and treatment of animal intestinal inflammation, and successfully realizes targeted delivery of therapeutic protein to intestinal tracts of mice. Experiments show that EcNpAm can effectively relieve typical symptoms such as weight loss, colon shortening, pathological injury, colitis and the like of mice induced by dextran sodium sulfate (DSS) and protect integrity and functions of an intestinal barrier structure.

The invention discloses a piglet intestinal health targeting probiotic engineering bacterium compound as well as preparation and application thereof. The compound is FP (at) EcN-pnirNKL, wherein a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin, and a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin; b) the recombinant plasmid pnirBMisL-NK-Lysin comprises an NK-Lysin gene optimized by a codon, and the NK-Lysin gene is integrated into the anaerobic inducible plasmid pnirBMisL through homologous recombination; c) the FP is a composite nano-particle which takes nano mesoporous silica (MSN) as a core and is formed by crosslinking fucoidin and rhodiola rosea polysaccharide; and d) the FP (at) EcN-pnirNKL is an oral delivery system which is formed by encapsulating the engineering bacterium EcN-pnirNKL in the FP nano particles. When the compound is applied to prevention and treatment of stress response of weaned piglets, various typical symptoms, including weight loss, colon shortening, histopathological injury and colitis disease response, of the piglets induced by dextran sodium sulfate can be remarkably relieved, and meanwhile, the integrity and functions of an intestinal barrier structure are effectively protected.

The invention discloses an application of a bee sugar plum seed alcohol extract in preparation of an anti-colitis medicine. The invention finds that the bee sugar plum seed alcohol extract inhibits the generation of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) under the condition of no cytotoxicity; the bee sugar plum seed alcohol extract inhibits transcription of LPS-induced pro-inflammatory cytokine genes and expression of genes and proteins of synthetic pro-inflammatory mediator enzymes (iNOS and COX-2); the bee sugar plum seed alcohol extract not only inhibits nuclear transfer of NF-kappa B by reducing phosphorylation and degradation of I kappa B alpha, but also inhibits phosphorylation of MPAKs (ERK, p38 and JNK); the traditional Chinese medicine composition has a remarkable inhibition effect on dextran sodium sulfate induced mouse colitis. Therefore, the bee sugar plum seed alcohol extract has a remarkable anti-inflammatory effect in vivo and in vitro, and can be used for treating colitis.

The present invention discloses a method for constructing an animal model of ankylosing spondylitis and chronic enteritis. By using proteoglycan PG immune induction and sodium dextran sulfate chemical induction methods, an animal model is established that simulates the coexistence of ankylosing spondylitis and chronic enteritis in terms of symptoms, imaging changes, and pathological characteristics. The model mice exhibit imaging changes similar to those of human ankylosing spondylitis, such as sacroiliac joint bone erosion and sclerosis, narrowing and roughening of the joint space, and worm-eaten changes. Furthermore, they exhibit pathological changes similar to those of human chronic enteritis, such as intestinal epithelial cell destruction, glandular disorder, crypt structure destruction, goblet cell reduction, and inflammatory cell infiltration. This model can be used to study the interaction mechanism between the two diseases, explore new therapeutic targets, and help evaluate the potential application of new drugs in the treatment of ankylosing spondylitis and chronic enteritis, providing an important tool for mechanism research and drug development of such co-morbidities.

The invention discloses a chitosan non-binding bilirubin microsphere as well as a preparation method and application thereof. The chitosan non-binding bilirubin microspheres are prepared by taking chitosan as a delivery carrier and taking chitosan and bilirubin as main raw materials through an emulsion reaction and a cross-linking reaction in sequence. Chitosan (CIS) is selected as a carrier for delivering unbound bilirubin (UCB), and the chitosan unbound bilirubin microspheres are prepared through an emulsion reaction and a cross-linking reaction, so that the UCB is more safely and efficiently fed into the intestinal tract to reach an inflammation part, and experiments prove that the UCB can be used for preparing the unbound bilirubin microspheres. The chitosan non-binding bilirubin microsphere has a remarkable protective effect on the intestinal immune function, microbiota disorder and barrier function of a dextran sodium sulfate (DSS) induced ulcerative colitis (UC) mouse.

The invention relates to the technical field of intestinal inflammation disease prevention and treatment, in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the invention is an active heptapeptide derived from natural protein, and has a clear chemical structure and a repeatable preparation process. Research results show that the polypeptide can significantly improve symptoms of mouse ulcerative colitis induced by dextran sodium sulfate (DSS), including weight loss reduction, disease activity index (DAI) reduction, colon length recovery, colon tissue pathological damage improvement and inflammation-related signal pathway inhibition, so that the improvement effect of the polypeptide on intestinal inflammation is verified. The polypeptide is prepared into a pharmaceutical composition or health-care food, so that the comprehensive effects of considering prevention and treatment and simultaneously improving inflammation and repairing barriers can be realized, and a new strategy and a material basis are provided for preventing and treating ulcerative colitis and other intestinal inflammatory diseases.

This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.

The invention belongs to the technical field of biomedicine, and particularly relates to application of ME1 in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The invention discloses an application of an ME1 inhibitor in preparation of drugs for preventing and / or treating inflammatory bowel diseases, and an application of a substance for detecting ME1 in preparation of drugs for diagnosing or detecting inflammatory bowel diseases. The action effect of ME1 * in disease treatment is evaluated through a mouse IBD model induced by dextran sodium sulfate DSS and trinitrobenzene sulfonic acid TNBS, so that a new strategy and method are provided for clinical intervention of IBD. In addition, the invention also clarifies the application of the ME1 as a high-specificity biomarker in IBD diagnosis, and further expands the comprehensive value of the ME1 in disease prevention and treatment.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

The invention discloses a colon-targeted Pickering emulsion stabilized by rhein-chitosan composite nanoparticles, a preparation method and an application of the colon-targeted Pickering emulsion. Rhein-chitosan is coupled and then crosslinked with sodium tripolyphosphate to form the rhein-chitosan composite nano-particles, and the nano-particles have better hydrophobicity and acid and alkali resistance stability; the nano-particle suspension and fish oil containing rhein are homogenized and emulsified at a high speed to obtain the Pickering emulsion entrapped with the rhein, and the Pickering emulsion has relatively high rhein drug loading capacity, better stability and good colon-specific release and slow release characteristics; and the traditional Chinese medicine composition has a dose-dependent relieving effect on dextran sodium sulfate induced ulcerative colitis mice, can inhibit inflammatory response and repair intestinal barrier functions, can effectively avoid intestinal nutrition loss caused by rhein, and has a good application prospect.

The application discloses curcumin nanoparticles with improved ulcerative colitis efficacy and a preparation method thereof. The application aims to solve the technical bottleneck that curcumin, an anti-inflammatory efficacy component, has poor stability and is difficult to reach the colon site, and provides a preparation method of curcumin nanoparticles with improved ulcerative colitis efficacy based on alkaline pH-mediated assembly and with colon-targeted delivery effect. The nanoparticles are all prepared from food raw materials, and the preparation process is simple, mild, controllable and easy to industrialize, does not involve any organic solvents and chemical reagents, and realizes efficient embedding of curcumin (the embedding rate is as high as 91.4%). The curcumin nanoparticles provided by the application can effectively alleviate the symptoms of dextran sodium sulfate-induced ulcerative colitis in mice in a dose-dependent manner, including improving body weight loss and colon shortening, and significantly inhibiting the expression of pro-inflammatory factors, and the effect is better than that of a conventional positive drug (mesalamine).

This invention discloses the application of psoralen in the preparation of FFA4 receptor agonists and drugs for FFA4 receptor-related diseases. Cellular experiments show that this compound is a concentration-dependent FFA4 agonist; animal experiments show that this compound has significant efficacy in a DSS-induced colitis model, reducing DSS-induced colonic shortening, improving weight loss, and alleviating splenic swelling. This compound can be used in the preparation of FFA4 agonists and in the prevention and treatment of FFA4-related diseases such as inflammatory bowel disease.

This invention, entitled "A Composition Containing Pentadecanoic Acid, Parabacterium Species Outer Membrane Vesicles Containing the Composition, and Their Applications," belongs to the field of probiotics and microbial preparations technology. The technical problem this invention aims to solve is that beneficial live bacteria have weak colonization ability in the gut, are easily affected by the gastrointestinal environment, exhibit unstable individual responses, and struggle to simultaneously address immune regulation and barrier repair. This invention provides a composition containing pentadecanoic acid, Parabacterium Species-derived outer membrane vesicles, and their applications. The outer membrane vesicles are derived from *Parabacterium difficile* and are rich in pentadecanoic acid, palmitic acid, and octadecanoic acid. The composition and outer membrane vesicles prepared by this invention can significantly inhibit macrophage M1 polarization and reduce pro-inflammatory cytokines. TNF-α , IL-6 and IL-1 β It can lower the expression level of [something], reduce intracellular reactive oxygen species levels, improve mitochondrial function, significantly alleviate symptoms of colitis induced by sodium dextran sulfate, regulate the intestinal flora structure, and increase the abundance of beneficial bacteria.

The invention relates to a probiotic composition and application thereof, and belongs to the technical field of compositions. Comprising Ackerman muciniphila ATCC BAA-835 and Bifidobacterium animalis subsp. Lactis BB-12, wherein the CFU (colony forming unit) ratio of the Ackerman muciniphila ATCC BAA-835 to the Bifidobacterium animalis subsp. Lactis BB-12 is 1 The two strains have a synergistic effect, and the prepared probiotic composition can synergistically relieve the phenomena of weight loss, colon shortening, intestinal structure and intestinal barrier injury, proinflammatory factor increase, anti-inflammatory factor reduction, intestinal flora and histidine metabolism disorder and the like of dextran sodium sulfate induced mouse ulcerative colitis. Therefore, the effect of preventing and relieving the severity of the inflammatory bowel disease is achieved.

The invention provides application of barley pest larva defatted protein powder in preparation of drugs for treating inflammatory bowel diseases. The invention belongs to the technical field of medicine, and by establishing a dextran sodium sulfate induced mouse IBD model and lavaging barley pest larva defatted protein powder, it is found that the traditional Chinese medicine composition can relieve IBD mouse colitis symptoms, restore colon length, relieve mucosal lesion, retain goblet cell and crypt structures, reduce inflammatory cell infiltration and down-regulate inflammatory cytokine expression; the compound is expected to play an important role in preparing medicines for treating inflammatory enteritis.

The application discloses a method for preparing high-value cellobiose from a medicine and food homologous Radix Millettiae and application of the high-value cellobiose. The method comprises the following steps: extracting cellulose from Radix Millettiae; optimizing a beta-glucanase enzymolysis process by using a response surface method; after the enzymolysis liquid is subjected to selective removal of glucose through yeast fermentation, the high-value cellobiose product is obtained through acetone precipitation and freeze-drying. The process condition is mild and environment-friendly, high-value utilization of agricultural waste is realized, the obtained cellobiose product has high purity, and an economic and effective approach is provided for large-scale production of cellobiose. Animal experiments prove that the cellobiose product has a significant relieving effect on colonitis induced by dextran sulfate sodium in mice, can effectively improve disease symptoms, reduce oxidative stress, repair intestinal barrier and regulate inflammatory response, and has a good application prospect in preparation of functional food or medicine for relieving colonitis and high-value utilization of Radix Millettiae.

The invention provides a preparation method of sodium dextran sulfate and application of the sodium dextran sulfate in red fading cosmetics, and relates to the technical field of catalytic synthesis. The preparation method comprises the following steps: S1, mixing glucan with the molecular weight of 1.5-30 thousand, beta-glucanase and a ZSM-5 molecular sieve to obtain pretreated glucan; s2, the pretreated dextran, a sulfonating reagent and a catalyst are mixed for a reaction, and dextran sulfate is obtained; s3, enabling the dextran sulfate to react with sodium salt, so as to obtain the dextran sulfate sodium. According to the specific preparation method disclosed by the invention, high-purity dextran sodium sulfate with specific molecular weight is obtained through specific raw materials, reaction conditions, refining steps, refining solvents and the like, and the stability is improved.

The invention relates to a water-based binder for a positive electrode of a lithium ion battery, a preparation method and application. The preparation method comprises the following steps: dissolving dextran sodium sulfate (DSS) in deionized water, adding a crosslinking reinforcing agent, and stirring and crosslinking at normal temperature to obtain the water-based adhesive. The aqueous binder can form a flexible and firm three-dimensional network structure on the whole positive electrode slurry, and the network structure can maintain the integrity of an electrode, effectively improve the first coulombic efficiency of a battery, inhibit voltage attenuation, enhance the conductivity of a positive electrode, accelerate reaction kinetics, optimize a transmission path and improve the stability of the battery. The charge-discharge cycle stability, the rate capability and the like of the battery are greatly improved, and the battery with stable capacity and long cycle life is obtained; within the voltage of 2-4.8 V, the 0.1 C first-circle discharge specific capacity can reach 296.7 mAh / g or above, the first efficiency is improved to 85.72% or above, and the capacity retention ratio after 300 cycles under the current of 1 C is 99.31% and 93.70% after 400 cycles. The preparation process is simple and environment-friendly, low in equipment requirement and low in energy consumption.

Provided is a method for preventing and alleviating inflammatory bowel disease by administering a composition including puer tea extract as an active ingredient to a subject in need thereof. Puer tea extract of the present disclosure showed an effect of improving damaged colonic tissue in a mouse model of acute ulcerative colitis induced by dextran sulfate sodium (DSS), and showed an inhibitory effect on clinical symptoms of the disease activity index (DAT) of weight loss, diarrhea, and rectal bleeding. In addition, puer tea extract inhibited the expression of inflammatory cytokines TNF-α and IL-6 in the colonic tissue and inhibited the inflammatory response through inhibition of the activity of NF-κB, an anti-inflammatory mechanism. In addition, the DPPH free radical and ABTS free radical scavenging ability increased proportionally as the concentration of puer tea extract increased at the cellular level, and COX-2 expression was inhibited in LPS-activated macrophages.

The application provides application of Elaeagnus conferta polysaccharide in preparation of a medicine for treating intestinal barrier related diseases, and relates to the technical field of natural medicine chemistry. The intestinal protection effect of the Elaeagnus conferta polysaccharide on a dextran sodium sulfate induced intestinal injury model of mice is investigated, and the research result shows that the Elaeagnus conferta polysaccharide can treat clinical symptoms such as diarrhea, enteritis and weight loss caused by intestinal barrier injury, significantly reduces disease scores, inhibits colonic tissue goblet cell necrosis, promotes secretion of mucin, increases expression of tight junction proteins, and enhances intestinal mucosal barrier function. As a widely planted fruit and a fruit loved by the public, the Elaeagnus conferta has the advantages of high safety and easy acquisition. It is expected to become an effective active ingredient source for resisting intestinal injury diseases, and has a broad market development prospect.

This invention provides the application of *Pleurotus oosporum* polysaccharide in the preparation of drugs and health foods that regulate intestinal barrier function or protect against intestinal damage-related diseases. Its protective effect against a mouse model of intestinal damage induced by sodium dextran sulfate was investigated. Results showed that *Pleurotus oosporum* polysaccharide significantly improved symptoms such as weight loss, loose stools, and colonic atrophy caused by intestinal damage in mice, reduced the disease activity index, inhibited colonic epithelial destruction, inflammatory cell infiltration, and goblet cell necrosis, and enhanced intestinal mucosal barrier function. As a fungus, *Pleurotus oosporum* has high safety and is a potential source of active ingredients against intestinal damage, showing promising development prospects in intestinal barrier protection.

The invention discloses resin, an adsorption material and a method for reducing the concentration of low-density cholesterol in blood. The resin is prepared by carrying out ring-opening reaction on dextran sodium sulfate and epoxy groups of modified polyethersulfone. Wherein the modified polyethersulfone is prepared by reacting polyethersulfone with an epoxy compound with a carbon-carbon double bond. The resin can be used as an adsorption material, and can be a porous film or a porous hollow fiber. The adsorbent material may contact the blood to reduce low density cholesterol concentrations in the blood.

The application provides use of an S1PR1 biased agonist in preparation of a drug for treating inflammatory bowel disease. The application proves through animal tests that, compared with a dextran sodium sulfate treated inflammatory bowel disease model group of mice, the colon length of mice added with SAR247799 treatment tends to be normalized, and finally the purpose of treating inflammatory bowel disease is achieved, and the application has a practical popularization and application prospect.

The application discloses a method for constructing an animal model of phlegm-dampness constitution and application of the method in evaluating intervention effect of body regulation, compared with a method for copying phlegm-dampness constitution by feeding mice with high-fat feed for a long time to cause metabolic disorder, the method provided by the application significantly improves the modeling effect by transplanting intestinal flora of a phlegm-dampness constitution subject into a pseudo-sterile mouse. Further, on the basis of high-fat feed combined with intestinal flora transplantation, the application surprisingly finds that the step of adding 0.5% dextran sodium sulfate in drinking water can further significantly improve the modeling rate of the phlegm-dampness constitution mouse animal model. The phlegm-dampness constitution mouse animal model obtained by the constructing method provided by the application can be used not only for evaluating intervention effect of body regulation, but also for studying pathogenesis of phlegm-dampness constitution and for screening and preparing drugs for intervention of body regulation of phlegm-dampness constitution.

The application relates to the technical field of animal model construction, and particularly discloses a Sypl1 gene knockout colorectal cancer mouse model construction method and application, which comprises the following steps: synthesizing a specific target site gRNA of a Sypl1 gene, mixing Cas9 protein and the target site gRNA to obtain an injection compound, microinjecting the injection compound into mouse zygotes, and transplanting the surviving zygotes into the oviducts of pseudopregnant female mice to obtain F0 generation mice, and the mice born after 20 days are Sypl1 gene knockout mouse animal models; and a chemical induction modeling method is used to construct a colorectal cancer model in wild type mice and gene knockout mice. The Sypl1 gene knockout mouse is constructed by using a CRISPR / Cas mediated genome engineering technology Sypl1 combined with the most widely used colorectal cancer chemical inducer azoxymethane / dextran sodium sulfate, a new colorectal cancer mouse model is constructed, compared with a traditional chemical induction model, the tumor formation rate can be significantly improved, and the tumor formation time can be shortened, and a more efficient animal model is provided for colorectal cancer research.

The application discloses application of guaiacol in preparation of a drug for treating ulcerative colitis. Cell experiment results show that the guaiacol can enhance the ability of macrophages to remove apoptotic cells; animal experiment results show that the guaiacol can significantly relieve the disease of a dextran sodium sulfate (DSS)-induced ulcerative colitis mouse, and the specific performance is that the guaiacol can slow down the weight loss degree of the colitis mouse, effectively reduce the disease activity index (DAI) of the colitis mouse, significantly inhibit the shortening of the colon of the colitis mouse, the infiltration of inflammatory cells and the mucosal damage, obviously reduce the level of a pro-inflammatory factor in serum of the mouse, and increase the level of a pro-inflammatory repair factor. In conclusion, the guaiacol has definite curative effect on ulcerative colitis, has no obvious side effect, and has a good prospect of being developed into a drug for treating ulcerative colitis.

To provide an external composition that enhances action of an expensive heparin analog with a limited amount of use.SOLUTION: An external composition contains a heparin analog by 0.01 to 0.3 mass% and sodium dextran sulfate by 0.1 to 2 mass%.SELECTED DRAWING: Figure 1

The invention relates to the technical field of animal model construction, and particularly discloses a construction method and application of a Sypl1 gene knockout colorectal cancer mouse model, and the construction method comprises the following steps: synthesizing a specific target site gRNA of a Sypl1 gene, uniformly mixing Cas9 protein and the target site gRNA to obtain an injection compound, microinjecting the injection compound into a mouse fertilized egg to obtain a Sypl1 gene knockout colorectal cancer mouse model. And transplanting the survival fertilized ova into the salpingtube of a pseudopregnant female mouse for 20 days to obtain a mouse which is an F0-generation mouse, obtaining a Sypl1 gene knockout mouse animal model, and constructing a colorectal cancer model in a wild type mouse and a gene knockout mouse by adopting a chemical induction modeling method. A Sypl1 gene knockout mouse is constructed through a CRISPR / Cas mediated genome engineering technology, a novel colorectal cancer mouse model is constructed in combination with a colorectal cancer chemical inducer azomethane / dextran sodium sulfate which is most widely applied at present, and compared with a traditional chemical induction model, the novel colorectal cancer mouse model has the advantages that the tumor formation rate can be remarkably increased, the tumor formation time can be shortened, and the tumor formation cost can be reduced. And a more efficient animal model is provided for colorectal cancer research.